http://www.systane.com/professional/SYSTANE_Free.asp Go APR MAY NOV
4 captures
28 May 2006 - 5 Jan 2007
2005 28 2006 2007
About this capture

Home
Dry Eye Cascade
Educational Video
Signs & Symptoms
Tear Break-Up Time
Ocular Protection Index
Tear Film Structure
The Role of Glycocalyx
How Instability Occurs
SYSTANE®
Extends TFBUT
Superior Lubricity
Compatible with Restasis*
Pre- & Post-Lens Wear Use
SYSTANE® FREE
A Gel in the Bottle
Minimal Blur Protection
Unique Preserving Action
Clinical Data

SYSTANE® FREE, the Minimal Blur Liquid Gel

SYSTANE® FREE Lubricant Eye Drops is a ***structured gel*** in the bottle that contains the active demulcents polyethylene glycol 400 (PEG) and propylene glycol (PG), and no traditional preservatives. (Original SYSTANE® is a solution in the bottle preserved with POLYQUAD* and formulated at a pH of 7.0.)

SYSTANE® FREE contains a novel system of proprietary ingredients including four that help form its gel structure and maintain its preservation:

- AMP† (a pH adjuster)
- Sorbitol (a sugar)
- Borate (buffer)
- Zinc (ion)

It is the combination of these ingredients that produce a low viscosity droppable gel and unique, ionic buffering preservation system.[1, 2, 3]

SYSTANE® FREE is NOT designed to replace SYSTANE® or SYSTANE® Preservative Free. **SYSTANE® FREE is another option for those patients who need the additional protection of a gel. Patients who are sensitive to preservatives and want the convenience of a multi-dose bottle can also benefit from SYSTANE® FREE.** SYSTANE® FREE joins the comprehensive family of SYSTANE® Lubricant Eye Drops, offering patients one more way to combat the irritable symptoms of dry eye.

1. Rosenthal R, Buck S, Schlech B. Rigorous microbiological testing of a multi-dose tear replacement formulation with no preservatives. J Amer Optom Assoc. Abst. June 2005; 765(6):398. Poster presented at: The Association for Research in Vision and Ophthalmology (ARVO); May 2005.
2. Rodeheaver D, Griffin J, Hendrix C, et al. Pre-clinical evaluation of a novel artificial tear (AT) for dry eye. Presented at: 4th International Conference on the Lacrimal Gland, Tear Film, Ocular Surface and Dry Eye Syndromes: Basic Science and Clinical Relevance; November 17-20, 2004; Fajardo, Puerto Rico.
3. Hoffman HM, Choi JH, Clousing DP, Ubels JL, Meadows DL. Pre-clinical in vitro testing of an artificial tear formulation with a novel preservation system. Accepted for presentation at: The Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting; 2006; Fort Lauderdale, Fla.

† Aminomethyl propanol.

* Trademarks are the properties of their respective owners.

© 2006 Alcon, Inc. All Rights Reserved. The information and materials within this section pertain to the U.S. market only. See Privacy Policy and Legal Terms for use of this site and Internet disclaimer.

Exhibit 1110
ARGENTUM
IPR2017-01053

DOCKET ALARM
Find authenticated court documents without watermarks at docketalarm.com.